Table 3.

Patient and transplant characteristics

PATIENT characteristics			Transplant characteristics
					Immunosuppression
Patient #	Age	Ethnicity	Indication	Single versus double	Induction agent	Calcineurin inhibitor maintenance	Antimetabolite maintenance	Steroid maintenance	mTOR inhibitor maintenance
1	76	Caucasian	COPD	D	N/A	TAC	None	Pred	N/A
2	73	Caucasian	IPF	D	BXB	TAC	None	Pred	N/A
3	67	Caucasian	IPF	R	BXB	CYC	None	Pred	N/A
4	74	Caucasian	IPF	L	AMB	TAC	MFM	Pred	N/A
5	61	Caucasian	IPF	R	BXB	TAC	None	Pred	N/A
6	74	Caucasian	COPD	D	BXB	TAC	None	Pred	N/A
7	60	Caucasian	CPFE	R	AMB	TAC	MFM	Pred	N/A
8	63	Caucasian	COPD	L	BXB	TAC	MFM	Pred	N/A
9	75	Caucasian	IPF	L	AMB	TAC	MFM	Pred	N/A
10	75	Caucasian	CPFE	R	BXB	TAC	MFM	Pred	N/A
11	76	Caucasian	IPF	L	BXB	TAC	MFM	Pred	N/A
12	61	Caucasian	ILD	L	AMB	TAC	MFM	Pred	N/A
13	73	Caucasian	COPD	L	BXB	TAC	AZA	Pred	N/A
14	80	Caucasian	CPFE	R	AMB	TAC	AZA	Pred	N/A
15	73	Caucasian	CPFE*	L	BXB	TAC	MFM	Pred	N/A
16	82	Caucasian	IPF	L	BXB	TAC	None	Pred	N/A
17	61	Caucasian	COPD	L	BXB	TAC	None	Pred	N/A
18	76	Caucasian	IPF	R	BXB	TAC	MFM	Pred	N/A
19	70	Caucasian	CPFE	R	AMB	TAC	AZA	Pred	N/A
20	63	Caucasian	IPF	R	AMB	TAC	MFM	Pred	N/A
21	76	African-American	COPD	L	BXB	TAC	MFM	Pred	N/A
22	66	Caucasian	COPD	L	BXB	TAC	MFM	Pred	N/A
23	59	Caucasian	COPD	R	AMB	TAC	None	Pred	N/A
24	58	Caucasian	IPF	L	BXB	TAC	MFM	Pred	N/A

*Features of bronchiectasis present with underlying CPFE.

AMB, alemtuzumab; AZA, azathioprine; BXB, basiliximab; COPD, chronic obstructive pulmonary disease; CPFE, combined pulmonary fibrosis with emphysema; CYC, ciclosporin; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; MFM, mycophenolate mofetil; mTOR, mammalian target of rapamycin; Pred, prednisone; TAC, tacrolimus.